Connect Biopharma (CNTB) vs Dogwood Therapeutics (DWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Connect Biopharma (CNTB) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 80.6% versus a loss of 83.7%. Over five years, CNTB leads with a -86.9% price change compared with -99.2% for DWTX. Dogwood Therapeutics is the larger company by market cap ($39.6 million vs $38.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | DWTX |
|---|---|---|
| Share price | $0.59 | $1.04 |
| Market cap | $38.05M | $39.57M |
| 1-day change | -6.08% | -2.36% |
| YTD return | -79.08% | -75.12% |
| 1-year return | -80.59% | -83.68% |
| 5-year return | -86.89% | -99.16% |
| P/E ratio (TTM) | — | 0.10 |
| EPS (TTM) | $-1.14 | $10.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $64.00K | — |
| Revenue growth (YoY) | -99.75% | — |
| Net income (latest FY) | $-55.48M | $-34.26M |
| Operating margin | -90740.63% | — |
| Net margin | -86687.50% | — |
| 52-week high | $3.82 | $7.04 |
| 52-week low | $0.55 | $0.901 |
| Distance from 52-week high | -84.55% | -85.31% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +896.61% | +1252.66% |
| Average volume | 3.98M | 89.88K |
| Shares outstanding | 64.49M | 38.23M |
| Employees | 64 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About Dogwood Therapeutics
DWTX stock →Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
CNTB vs DWTX FAQ
Which is bigger, Connect Biopharma or Dogwood Therapeutics?
Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $39.57M compared with $38.05M for Connect Biopharma (CNTB).
Which stock has performed better over the past year, CNTB or DWTX?
CNTB returned -80.59% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Dogwood Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.